JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B 2014 Vol.15 No.9 P.761-765

Forty years of the war against Ebola

Author(s): Lei Zhang¹, Hao Wang²
Affiliation(s): 1. Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China; more
Corresponding email(s): biotech@china.com
Key Words: Ebola virus, Outbreak, ZMapp

Share this article to： More \|Next Article >>>

Lei Zhang, Hao Wang. Forty years of the war against Ebola[J]. Journal of Zhejiang University Science B, 2014, 15(9): 761-765.

@article{title="Forty years of the war against Ebola",
author="Lei Zhang, Hao Wang",
journal="Journal of Zhejiang University Science B",
volume="15",
number="9",
pages="761-765",
year="2014",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1400222"
}

%0 Journal Article
%T Forty years of the war against Ebola
%A Lei Zhang
%A Hao Wang
%J Journal of Zhejiang University SCIENCE B
%V 15
%N 9
%P 761-765
%@ 1673-1581
%D 2014
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1400222

TY - JOUR
T1 - Forty years of the war against Ebola
A1 - Lei Zhang
A1 - Hao Wang
J0 - Journal of Zhejiang University Science B
VL - 15
IS - 9
SP - 761
EP - 765
%@ 1673-1581
Y1 - 2014
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1400222

Abstract
Chinese Summary
Academic Network
Reviewer Comment

Abstract:

埃博拉之役四十年

本文概要：埃博拉病毒疫情自1976年在苏丹南部和旧扎伊尔的埃博拉河地区初次爆发，三年后在苏丹同一地区小规模复发一次后则沉寂了15年。1994年在加蓬地区再次突然复苏，至今在非洲多国已反复爆发15次，造成了4362人感染，2659人死亡。2014年，西非几内亚、利比里亚、尼日利亚和塞拉利昂爆发了历史上最严重和情况最复杂的疫情，局面失控。埃博拉病毒流行无明显的季节性，人群普遍易感且无性别差异，其天然宿主仍不确定。近四十年，疫情在一个地区消散后不知何时会在另一个地区突然暴发，被形容为像光的波粒二象性一般难以理解。由于埃博拉病毒对人体多器官普遍攻击而防范困难，加之开发病毒防治药物项目资金匮乏，人类至今没有找到能有效对抗埃博拉疫情的预防及治疗措施
埃博拉病毒；爆发；ZMapp

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

References

[1] Basler, C.F., Amarasinghe, G.K., 2009. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res, 29(9):511-520.

[2] CDC (US Centers for Disease Control and Prevention), 2014. Ebola outbreaks 2000–2014. , Available from http://www.cdc.gov/vhf/ebola/resources/outbreaks.html,:

[3] Feldmann, H., 2014. Ebola—a growing threat?. New Engl J Med, in press,:

[4] Geisbert, T.W., Jones, S., Fritz, E.A., 2005. Development of a new vaccine for the prevention of Lassa fever. PLoS Med, 2(6):e183

[5] Gupta, M., Mahanty, S., Ahmed, R., 2001. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1α and TNF-α and inhibit poly-IC-induced IFN-α in vitro . Virology, 284(1):20-25.

[6] Jahrling, P.B., Geisbert, T.W., Geisbert, J.B., 1999. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis, 179(S1):S224-S234.

[7] Johnson, K.M., Lange, J.V., Webb, P.A., 1977. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet, 309(8011):569-571.

[8] Kondratowicz, A.S., Lennemann, N.J., Sinn, P.L., 2011. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus . PNAS, 108(20):8426-8631.

[9] Leroy, E.M., Kumulungui, B., Pourrut, X., 2005. Fruit bats as reservoirs of Ebola virus. Nature, 438(7068):575-576.

[10] Miller, E.H., Obernosterer, G., Raaben, M., 2012. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J, 31(8):1947-1960.

[11] Mupapa, K., Massamba, M., Kibadi, K., 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis, 179(S1):S18-S23.

[12] Pettitt, J., Zeitlin, L., Kim, D.H., 2013. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med, 5(199):199ra113

[13] Rastogi, J., 2014. Canadians leading anti-Ebola research. Canad Med Assoc J, in press,:

[14] Reardon, S., 2014. Ebola treatments caught in limbo. Nature, 511(7511):520

[15] Report of an International Commission, 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ, 56(2):271-293.

[16] Smith, M., Hensley, L.E., Geisbert, T.W., 2013. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and marburg hemorrhagic fever. J Infect Dis, 208(2):310-318.

[17] Tekmira Pharmaceuticals Co., 2014. Tekmira receives fast track designation from FDA for its anti-Ebola viral therapeutic. , Available from http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=830680,:

[18] Wamala, J., Lukwago, L., Malimbo, M., 2010. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007–2008. Emerg Infect Dis, 16(7):1087-1092.

[19] WHO (World Health Organization), 2014. Disease outbreak news. , Available from http://www.who.int/csr/don/en/,:

[20] WHO (World Health Organization), 2014. Ebola virus disease. , Fact sheet N°103, updated April 2014,Available from http://www.who.int/mediacentre/factsheets/fs103/en/,:

[21] WHO (World Health Organization), 2014. Ethical considerations for use of unregistered interventions for Ebola virus disease (EVD). , Available from http://www.who.int/mediacentre/news/statements/2014/ebola-ethical-review-summary/en/,:

Similar articles

- Go to

埃博拉之役四十年

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

References